Flag of the European Union EU Clinical Trials Register Help

Clinical trials for vaccine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,995 result(s) found for: vaccine. Displaying page 26 of 100.
    «« First « Previous 22  23  24  25  26  27  28  29  30  Next» Last»»
    EudraCT Number: 2010-018991-25 Sponsor Protocol Number: GPF18 Start Date*: 2010-03-15
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity of the Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine Without Adjuvant in Healthy Adult Subjects
    Medical condition: Preventive vaccination in healthy subjects aged 18 to 60 years against infection with S-OIV (Swine Origin Influenza Virus) A/California/7/2009 (H1N1)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-002613-34 Sponsor Protocol Number: NL76336.041.21 Start Date*: 2021-06-30
    Sponsor Name:University Medical Center Utrecht
    Full Title: Prospective monitoring of antibody response following COVID-19 vaccination in patients with Down Syndrome
    Medical condition: Persons with Down syndrome
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002088-23 Sponsor Protocol Number: DemiVac2021 Start Date*: 2021-05-05
    Sponsor Name:Sciensano
    Full Title: Covid-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine in a Healthy Population (REDU-VAC)
    Medical condition: Healthy persons from age 18 till age 56
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003528-39 Sponsor Protocol Number: V503-001 Start Date*: 2007-11-15
    Sponsor Name:Merck & Co. Inc.
    Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavi...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, ...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Completed) SE (Completed) DE (Completed) AT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-004708-21 Sponsor Protocol Number: A3L44 Start Date*: 2019-07-23
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine Given as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and in HIV-Exposed Uninfected In...
    Medical condition: DTaP-IPV-HB-PRP-T Combined Vaccine in Human Immunodeficiency Virus Exposed Infected and Uninfected Infants
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-005604-15 Sponsor Protocol Number: 115887 Start Date*: 2015-10-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, randomised, controlled, single-blind study to evaluate the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ HPV-16/18 L1 VLP AS04 vaccine administered according to a 2-d...
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Children, Under 18 Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-000060-17 Sponsor Protocol Number: 200255 Start Date*: 2014-05-09
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open-label, non-randomised, multicentre study to assess the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine when administered intramuscularly according to ...
    Medical condition: Healthy volunteers [For active immunisation of females from 9 years of age onwards for the prevention of persistent infection, premalignant genital (cervical, vulvar and vaginal) lesions and cervic...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004865 10071147 Human papilloma virus immunization LLT
    16.1 100000004848 10058580 Human papilloma virus serology test LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005477-22 Sponsor Protocol Number: 107495 Start Date*: 2007-01-22
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open, randomized study in adults aged between 18 and 60 years designed to evaluate the reactogenicity and immunogenicity of a 1- and 2-dose prime-boost concept of pandemic monovalent (H...
    Medical condition: Immunization against influenza disease during pandemic in subjects aged 18 to 60 years.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003391-74 Sponsor Protocol Number: 106794 Start Date*: 2016-05-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Persistence of hepatitis B antibodies, immunogenicity and safety of GSK Biologicals’ hepatitis B vaccine, Engerix™-B Kinder (SKF103860) challenge dose, in adolescents vaccinated with four doses of ...
    Medical condition: Immunisation against infection caused by all known subtypes of hepatitis B virus.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003094-15 Sponsor Protocol Number: V98_06E1 Start Date*: 2016-02-11
    Sponsor Name:GlaxoSmithKline Biologicals S.A.
    Full Title: A Phase 2, Non-Randomized, Controlled, Open-Label, Parallel-Group, Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-pregnant Subj...
    Medical condition: Healthy person immune response to a second dose of Group B Streptococcus polysaccharide capsule antigens
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10053588 Group B streptococcus neonatal sepsis PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013075-21 Sponsor Protocol Number: V72P9E1 Start Date*: 2009-08-18
    Sponsor Name:Novartis Vaccines and Diagnostics Srl.
    Full Title: A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence compared to Naïve Children and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV ...
    Medical condition: The Novartis Meningococcal B recombinant vaccine is intended for prevention of meningitis and/or septicemia caused by Neisseria meningitidis serogroup B. The objective of the Novartis Meningococcal...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001484-39 Sponsor Protocol Number: 444563/022 Start Date*: 2015-06-11
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, double-blind, randomized, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated huma...
    Medical condition: Rotavirus Gastroenteritis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001103-77 Sponsor Protocol Number: FLU007INVICTUS Start Date*: 2017-09-05
    Sponsor Name:Vaccitech Limited
    Full Title: A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed InaCTivated inflUenza vaccine in adultS aged 65 years and above
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10016790 Flu LLT
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005102-30 Sponsor Protocol Number: OVG2011/05 Start Date*: 2011-12-08
    Sponsor Name:University of Oxford
    Full Title: A phase III randomised, open label clinical trial evaluating the immunogenicity of a 10-valent pneumococcal conjugate vaccine booster compared to the standard 13-valent pneumococcal conjugate vacci...
    Medical condition: The study will include healthy children who have already been vaccinated with 2 doses of Prevenar 13 according to the UK routine immunisation schedule at 2 and 4 months of age. Both vaccines used i...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005860-31 Sponsor Protocol Number: 111870 Start Date*: 2015-06-25
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Immunogenicity of GlaxoSmithKline Biologicals’ MMR vaccine (209762) vs. M-M-R® II, when co-administered with hepatitis A, varicella and pneumococcal conjugate vaccines to children 12-15 months of age
    Medical condition: Diseases caused by measles, mumps, rubella and varicella viruses
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003427-10 Sponsor Protocol Number: 111157 Start Date*: 2015-05-04
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open-label, randomised, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ combined DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) administered to I...
    Medical condition: Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, polio and Hib diseases.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-013904-30 Sponsor Protocol Number: V111_04 Start Date*: 2009-07-14
    Sponsor Name:NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
    Full Title: A Phase II, Open Label Study to Evaluate the Immunogenicity, Tolerability and Safety of a MF59-Adjuvanted, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Heal...
    Medical condition: Evaluate the Immunogenicity, Tolerability and Safety of a MF59-Adjuvanted, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects Aged 18 Years and Above
    Disease: Version SOC Term Classification Code Term Level
    12.0 10022000 Influenza LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-005387-25 Sponsor Protocol Number: noprofit1616 Start Date*: 2016-05-05
    Sponsor Name:Sapienza, University of Rome
    Full Title: Phase 2a Study of an Immunotherapeutic Vaccine, DPX-Survivac, Alone or with Low dose Cyclophosphamide in Primary Glioblastoma Patients Receiving Standard of Care Therapy
    Medical condition: Glioblastoma is the most common primary brain tumour in humans with the most severe prognosis. Standard treatments consist primarily of surgery in order to debulk thetumoral mass, as well as radioc...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10045172 Tumour vaccine therapies HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000710-42 Sponsor Protocol Number: RR-xx-RTX-COVAC Start Date*: 2021-03-15
    Sponsor Name:Sint Maartenskliniek
    Full Title: The RTX-COVAC study: humoral response to COVID-19 vaccination after rituximab, and relation with dose and vaccination timing. A prospective cohort study.
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004813-37 Sponsor Protocol Number: V89_11 Start Date*: 2022-04-14
    Sponsor Name:Seqirus Inc. formerly Novartis Vaccines and Diagnostics Inc.
    Full Title: A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Dif...
    Medical condition: Prophylaxis for Influenza virus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 22  23  24  25  26  27  28  29  30  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 30 01:16:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA